logo-loader
viewFutura Medical PLC

Futura Medical's James Barder says regulatory submissions for MED3000 remain on track

Futura Medical PLC's (LON:FUM) James Barder tells Proactive London's Andrew Scott they've seen little impact from the coronavirus lockdown and that regulatory submissions for its erectile dysfunction treatment remain on track.

The treatment is MED3000 - a fast-acting gel that will be targeted at men for whom the current treatments don’t work.

Barder says a second pre-submission meeting with the US Food & Drug Administration has been now set.

Quick facts: Futura Medical PLC

Price: 16 GBX

AIM:FUM
Market: AIM
Market Cap: £39.3 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical CEO talks regulatory timeline and commercial potential for...

Futura Medical PLC's (LON:FUM)  James Barder caught up with Proactive London's Andrew Scott on the back of their 2019 results. He says the EU filing for MED3000 is likely by the end of July, with the US Food & Drug Administration submission expected by the end of the third...

on 1/4/20

2 min read